Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis.

Papp, Kim

Papp, Kim.

Affiliation

Papp K; Probity Medical Research Inc., Waterloo, Ontario, Canada. kapapp@probitymedical.com

Curr Med Res Opin ; 26(10): 2287-300, 2010 Oct.

Article in En | MEDLINE | ID: mdl-20718590

Subject(s)

Psoriasis/drug therapy; Receptors, Tumor Necrosis Factor, Type I/therapeutic use; Tumor Necrosis Factor Decoy Receptors/therapeutic use; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Discovery; Hormone Antagonists/adverse effects; Hormone Antagonists/chemical synthesis; Hormone Antagonists/pharmacology; Hormone Antagonists/therapeutic use; Humans; Protein Binding; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor, Type I/adverse effects; Receptors, Tumor Necrosis Factor, Type I/chemical synthesis; Receptors, Tumor Necrosis Factor, Type I/pharmacology; Systemic Inflammatory Response Syndrome/chemically induced; Systemic Inflammatory Response Syndrome/epidemiology; Treatment Outcome; Tumor Necrosis Factor Decoy Receptors/adverse effects; Tumor Necrosis Factor Decoy Receptors/chemical synthesis; Tumor Necrosis Factor Decoy Receptors/pharmacology; Tumor Necrosis Factor-alpha/antagonists & inhibitors; Tumor Necrosis Factor-alpha/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Receptors, Tumor Necrosis Factor, Type I / Tumor Necrosis Factor Decoy Receptors Type of study: Clinical_trials / Evaluation_studies / Prognostic_studies Limits: Animals / Humans Language: En Journal: Curr Med Res Opin Year: 2010 Document type: Article

Fulltext

XML

PubMed Links

Search on Google